Significant liver uptake often limits the clinical application of radiolabeled antibodies in
radioimmunodetection. The purpose of this study was to evaluate the γ-imaging properties of an …

Background Improved survival of children with malignant diseases is in part due to the
application of intensive, multimodality therapies, including radiotherapy, surgery, glucocorticoids, …

… Delpassand et al. presented a Phase 2 nonrandomized clinical trial, which included 37
patients with grades 1 and 2 disseminated and progressive gastroenteropancreatic NET who …

Emerging evidence indicates that tumor-associated proteolytic remodeling of bone matrix may
underlie the capacity of tumor cells to colonize and survive in the bone microenvironment. …

… Since the mid 1980’s the US nuclear power industry has embarked on a program to design,
license, and be ready to build new nuclear power plants in the US and abroad. This program …

The concept of using a targeting molecule labeled with a diagnostic radionuclide for using
positron emission tomography or single photon emission computed tomography imaging with …

Most well-differentiated neuroendocrine tumors (NETs) express high levels of somatostatin
receptors, particularly subtypes 2 and 5. Somatostatin analogs (SSAs) bind to somatostatin …

Bisphosphonates are therapeutic agents that have been used for almost five decades in the
treatment of various bone diseases, such as osteoporosis, Paget disease and prevention of …

Peptide receptor radionuclide therapy (PRRT) using 177 Lu-DOTATATE has been approved
for the treatment of gastroenteropancreatic NETs. An understanding of benefits and risks is …

Targeted radionuclide therapy plays an increasingly important role in managing endocrine-related
tumors and significantly advances the therapeutic landscape for patients with these …